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Abstract
Background: COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in
low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor
for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor
for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the
efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither
available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy,
long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the
absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-
Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose
theophylline for the management of biomass-related COPD in a low-income setting.
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Methods: LODOT-BCOPD is a randomized, double-blind, placebo-controlled trial to test the efficacy of low-dose
theophylline in improving respiratory symptoms in 110 participants with moderate to severe COPD in Central Uganda.
The inclusion criteria are as follows: (1) age 40 to 80 years, (2) full-time resident of the study area, (3) daily biomass
exposure, (4) post-bronchodilator FEV1/FVC below the 5th percentile of the Global Lung Initiative mixed ethnic
reference population, and (5) GOLD Grade B-D COPD. Participants will be randomly assigned to receive once daily low-
dose theophylline (200mg ER, Unicontin-E) or placebo for 52 weeks. All participants will receive education about self-
management of COPD and rescue salbutamol inhalers. We will measure health status using the St. George’s Respiratory
Questionnaire (SGRQ) and quality of life using the EuroQol-5D (EQ-5D) at baseline and every 6 months. In addition, we
will assess household air pollution levels, serum inflammatory biomarkers (fibrinogen, hs-CRP), and theophylline levels
at baseline, 1 month, and 6months. The primary outcome is change in SGRQ score at 12months. Lastly, we will assess
the cost-effectiveness of the intervention by calculating quality-adjusted life years (QALYs) from the EQ-5D.
Trial registration: ClinicalTrials.gov NCT03984188. Registered on June 12, 2019
Trial acronym: Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD)
Keywords: Biomass, COPD, Theophylline
Introduction
Regular inhalation of toxins, such as tobacco smoke, can
result in chronic obstructive pulmonary disease (COPD),
a heterogeneous disease marked by largely irreversible
airflow obstruction of the small airways, chronic
bronchitis, and emphysema due to complex gene-
environment interactions over the lifetime [1, 2]. COPD
affects approximately 328 million people worldwide and
is a leading cause of death globally [3]. The vast majority
(~ 90%) of morbidity and mortality occurs in low- and
middle-income country (LMIC) settings. Although to-
bacco smoke is a leading risk factor for COPD globally,
a significant proportion (20–30%) of COPD occurs among
never smokers [4, 5].
Household air pollution (HAP) from biomass combus-
tion is an important risk factor in the development of
COPD in many LMICs. Globally, nearly three billion
people rely on biomass, which includes wood, dung, and
agricultural crop waste or coal, for cooking and heating
[6]. Individuals exposed to HAP in LMICs are 41% more
likely to have COPD than those without the exposure
[7]. Biomass-associated COPD has a distinct histopath-
ology, phenotype and inflammatory profile when compared
to tobacco-mediated COPD, suggesting a differential
response to treatment and disease prognosis compared to
tobacco-mediated disease [1, 8]. Despite the high global
burden of biomass-associated disease, little is known about
the effectiveness of pharmacotherapies for biomass-
associated COPD; to date, no clinical trials have focused
specifically on treatment of biomass-associated COPD [8].
Theophylline has been used in the treatment of
chronic obstructive airway diseases, including COPD
and asthma, and remains widely prescribed worldwide,
largely due to its low expense [9]. In many high-income
countries, the frequency of side effects and the drug’s
narrow therapeutic index, together with wide availability
of newer and more effective therapies, notably long-
acting bronchodilators, have led to reduced usage for
management of COPD. However, a number of studies
have demonstrated that theophylline at lower doses (1–
5 mg /L) results in improved respiratory symptoms via
transcriptional downregulation of inflammatory genes
[10–12]. Therapeutic monitoring is not necessary at
such doses. Low-dose theophylline has been proposed as
a treatment for biomass-associated COPD in LMICs,
where inhaler-based therapy for COPD is usually un-
affordable, not available or both [9, 13]. Although no tri-
als have been designed to evaluate the cost-effectiveness
of treatment for COPD in LMICs, economic modeling
demonstrates that annual per-capita costs for managing
COPD with inhaler-based therapy would amount to
USD 13,000–14,000 per disability adjusted life year
(DALY) averted, well above cost-effectiveness benchmarks
[14]. Previous studies among individuals with tobacco-
associated COPD have demonstrated low-dose theophylline
monotherapy results in improved lung function (FEV1), re-
duced respiratory symptoms, and decreased the frequency
and duration of exacerbations [15].
The main objective of the Low-dose Theophylline for
the Management of Biomass-Associated COPD (LODOT-
BCOPD) trial is to assess the clinical efficacy and cost-
effectiveness of low-dose theophylline for the management
of biomass-associated COPD in a low-income setting.
Design and methods
Study setting
Uganda is a low-income country located in East Africa
with a total population of 45 million and a million, over
80% of whom live in rural areas. The study will be
carried out in Nakaseke, Central Uganda, a district
covering 43,167 households with an estimated population
of 208,500. Nakaseke is located 14 km from the nearest
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highway and has been defined as rural by the Uganda
Bureau of Statistics [16]. Most of the inhabitants (75%) are
subsistence farmers, and over 60% of them live on less
than 45,000 shillings ($12) per month [16]. The ratio of
physicians and nurses per person are 1:25,000 and 1:5000,
respectively, making Nakaseke one of the most under-
resourced health districts in Uganda. We have previously
conducted a population-based study in Nakaseke using
spirometry to assess the prevalence of COPD [17].
Study population
For this study, we will enroll adults with grade B-D
COPD living in Nakaseke, previously identified in the
GECo study [17, 18]. GECo was a population-based
study which enrolled 3624 participants to validate case-
finding instruments and assess the effectiveness of
COPD self-management plan. The inclusion criteria are
as follows: (1) age 40 to 80 years, (2) full-time resident of
Nakaseke (lived in the area for > 3 years), (3) daily bio-
mass exposure, (4) post-bronchodilator FEV1/FVC below
the lower limit of normal of the Global Lung Initiative
Mixed Ethnic reference population [19, 20], and (5)
GOLD Grade B-D COPD [2]. Exclusion criteria include
the following: (1) plans to relocate within 1 year; (2)
uncontrolled hypertension; (3) pregnancy; (4) current
use of chronic respiratory medications (long-acting
bronchodilators (LABA), long-acting muscarinic agents
(LAMA), and inhaled corticosteroids (ISC); (5) pulmon-
ary tuberculosis; (6) > 10 pack year tobacco smoking
history and/or active smoking; and (7) known intoler-
ance or contraindication to theophylline. All participants
will additionally be COVID-19 tested by nasopharyngeal
RT-qPCR 72 h prior to study visit.
Study design
We will enroll 110 adults in a randomized, double-blind,
placebo-controlled trial to receive either daily 200mg ER
low-dose theophylline (“intervention”) or placebo (“con-
trol”) (Fig. 1). The primary outcome of the trial will be to
assess the clinical efficacy of low-dose theophylline at 12
months as determined by differences in health states as
measured by the St. George’s Respiratory Questionnaire
(SGRQ). Secondary outcomes will include (a) differences
in lung function decline and reversibility defined by ATS/
ERS [21] and (b) differences in health-related quality of life
measured by the Euro-Qol 5D (EQ-5D). We will addition-
ally evaluate the biologic activity of low-dose theophylline
in subjects by measuring circulating inflammatory
biomarkers and assess whether theophylline decreased
inflammation. Finally, we will estimate the incremental
cost-effectiveness of the intervention.
Participants in the intervention group will be provided
with a monthly supply of low-dose theophylline tablets
in childproof bottles by trained research assistants. Both
arms will additionally receive COPD specific education
and salbutamol inhalers per standard care [22]. All
participants will be followed monthly for a period of 12
months.
Fig. 1 Recruitment diagram
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Ethics
The trial protocol was approved by the Institutional
Review Boards (IRB) at Johns Hopkins School of
Medicine (IRB 209008), the University of Miami (IRB
20201523), The Makerere College of Health Sciences
School of Medicine (REF 2020-093), and the Uganda
National Council of Science and Technology (HS 2758).
The trial was also registered with ClinicalTrials.gov
(Identifier: NCT03984188) on June 12, 2019. Prior to
any data collection, research staff will explain study
purpose and procedures to participants, emphasizing
that participation is completely voluntary and partici-
pants can choose to withdraw from the study at any
time. Participants will also be provided with an informa-
tion sheet. Written consent will be obtained from each
participant for the present study and future ancillary
studies, if applicable. In situations where a participant is
unable to read or write, a thumbprint will be obtained,
along with written signature from a witness. Access to
identifiable individual-level data will be restricted to an
independent study clinician and trial pharmacist. Protocol
amendments will be approved by all regulatory parties
prior to change in research activities.
Training
All research personnel will receive human subjects
training. Research assistants will be trained in electronic
data capture and spirometry. Community health workers
(CHWs) with experience in chronic respiratory diseases
will provide COPD education [17]. CHWs have previously
been educated on COPD pathophysiology, common treat-
ments and their mechanism of action, as well as Ugandan
guidelines for the diagnosis, management, and treatment
of COPD, and familiarization with project goals.
Recruitment, enrollment, and retention
Individuals with previously identified COPD will be
recruited from the GECo study [17]. GECo was a
population-based study which screened 3634 partici-
pants for COPD and enrolled subjects into a self-
management trial. Trained research assistants will visit
households to contact potential participants and invite
them to the study. Before enrollment, study personnel
will explain the goals of the study, what the study entails
for the participant, and then ask if they are interested in
participating. Those who agree to participate will be
asked to complete detailed socioeconomic, medical his-
tory and exposure questionnaires and have spirometry
performed for confirmatory testing.
Randomization
Once a participant is determined to be eligible and
agrees to enter the study, research assistants will block
randomize them to each of the two groups using the
automated randomization feature in REDCap (Vander-
bilt University Medical Center, Nashville, TN, USA).
Participants will be followed monthly for a 1-year period,
and enrollment will be staggered over a 1-year period.
Principal investigators, members of the data coordinat-
ing center, and participants will be blinded to treatment
allocation. Unblinding will occur only at the discretion
of the data and safety monitoring board (DSMB) or at
time of final analysis.
Study arms
Individuals randomized to the intervention arm will
receive locally sourced low-dose theophylline (200 mg
ER, Unicontin-E, Modi Mundi Pharma Pvt. Ltd.). Con-
trol randomized participants will receive methylcellulose
placebo pills (Kampala Pharmaceutical Industries Ltd.)
in identical packaging. The standard care for COPD as
per WHO guidelines (salbutamol inhalers as needed)
will be provided to all study participants, regardless of
group assignment, by study clinicians. We will utilize
standard dosing by ideal body weight (IBW). IBW is
computed by using the Devine formulae: IBWfemale =
45 + 0.9 (height in cm – 152) kg and IBWmale = 50 + 0.9
(height in cm – 152) kg [23]. A dose of theophylline ER
200mg once daily (one placebo once daily) will be dis-
tributed to participants [24].
Study outcomes
We will follow-up participants at 1 month, 6 months,
and 12months during face-to-face assessments in a
clinical setting (Figs. 1, 2, and 3). In the event that a
participant is unable to attend a scheduled follow-up
assessment visit because of an acute illness (e.g., exacerba-
tion of COPD) or other reasons, the visit can be post-
poned, to within 2 weeks of the scheduled assessment
visit. Research assistants will additionally perform monthly
visits to assess medication adherence, refill medications,
and assess for adverse events.
COPD questionnaires
The primary outcome of the trial will be a comparison
of the change in SGRQ at 6 month increments from
baseline to 12months between the two arms [25]. The
SGRQ measures impaired health and perceived well-
being among individuals with chronic airway disease and
offers many advantages for our study, namely (i) can be
used to quantify changes in health following treatment,
(ii) it is not limited to individuals with COPD, and (iii) it
provides a standard metric that can be used for easy
comparison across settings [25, 26]. We have previously
validated the SGRQ in Luganda, the most widely
spoken language in Nakaseke [27]. We will addition-
ally administer the COPD Assessment Test (CAT) at
6-month increments. The CAT measures the impact
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of COPD (cough, sputum, dyspnea, chest tightness)
on health status [28].
Quality of life
The EuroQol-5D (EQ-5D) questionnaire will be admin-
istered at baseline and every 6months through the trial
period. The EQ-5D is a generic instrument for measur-
ing health utility. It is based on a descriptive system that
defines health in 5 dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression [29].
Each dimension has 3 response categories corresponding
to no problems, some problems, and extreme problems.
The instrument is designed for self-completion, and re-
spondents also rate their overall health on the day of the
interview from 0 to 100 hash-marked, visual analog scale
(EQ-VAS). Quality-adjusted life years (QALYs) will be
derived using health utilities as estimated from the EQ-
5D. The EQ-5D has been widely tested and used in both
general populations and patient samples and has been
locally validated in Uganda [29].
Lung function
Spirometry will be conducted on all participants before
and after bronchodilator therapy (400 mcg of salbutamol
using a spacer) following standardized guidelines [19].
We will use the Easy on-PC handheld spirometer (ndd,
Zurich, Switzerland), a device that has been validated
and used in several large population-based studies [30, 31].
We will record post-bronchodilator PEF, FEV1, and FVC.
Biomarkers
We will assess fibrinogen levels, a biomarker for all-
cause mortality and exacerbations among those with
COPD [32–34]. We will additionally measure serum hs-
CRP and blood eosinophils. We will conduct blood
draws at baseline, 6 months, and 12 months with the
Fig. 3 Schedule of enrollment, interventions, and assessments for participants
Fig. 2 Schedule of enrollment, interventions and assessments
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aim of assessing response to theophylline as well as
identifying sub-groups which may have a differential
response to therapy. We will process and store serum
samples in Uganda at − 80 °C for future analysis. Samples
will be destroyed at the request of participants.
COPD exacerbations
We will utilize ATS/ERS guidelines regarding exacerba-
tion definition and severity. A COPD exacerbation will
be defined as a worsening of patient’s dyspnea, cough, or
sputum beyond day-to-day variability [35]. Exacerbations
will be treated with antibiotics and/or oral corticoste-
roids by study clinicians per standard protocol in both
arms. A minimum of 2 weeks between consecutive exac-
erbations/hospitalizations will be used to consider events
as separate in follow-up analysis [24].
Health-care utilization
Data on participant health care utilization will be col-
lected. We will additionally collect data on concomitant
medications/studies, outpatient visits, and any-cause
hospitalizations during the previous month.
HAP measurements
We will measure personal PM2.5 concentrations using
the UPAS (Access Sensor Technologies, Fort Collins,
CO), a gravimetric and real-time sampler. We will
additionally collect continuous PM2.5 data using the
OPC-N3 (Alpha Sense, Essex, UK). Participants will be
encouraged to wear the monitors continuously during
the 48-h period and to keep close while sleeping. Black
carbon content of each personal filter will be determined
using a validated optical attenuation measure [36, 37].
Medication adherence
We will measure adherence to prescribed medications at
baseline and during follow-up visits. First, we will use
the Adherence to Refills and Medications Scale-7
(ARMS-7) [38]. ARMS-7 will be administered at baseline
and monthly during the follow-up period. The score is
calculated by summing the scores for all items; lower
scores indicate better adherence. Second, we will collect
empty drug bottles and unused medication; compliance
will be assessed by pill count [39]. Third, we will meas-
ure inhaler use by counters placed on salbutamol.
Statistical analysis plan
The primary study outcome will be to assess whether
the low-dose theophylline intervention results in
improved mean self-reported respiratory symptoms
(SGRQ) compared to standard care at 12 months. For
repeated outcome measurements (e.g., SGRQ, CAT,
PEF, FEV1, FVC, serum biomarkers), linear mixed effects
models will be used to account for within-subject
correlation. The main analysis will be by modified
intention-to-treat (ITT) based on cases where the
primary outcome is available and will therefore rely on
an assumption that data is missing at random. We will
describe the number (%) with missing primary outcome,
look at reasons for missing the outcome, and consider
characteristics of the patients excluded from the ITT
analysis. Multiple imputation for the primary analysis
will be used if the missing data exceeds 10% of random-
ized patients and as a secondary analysis regardless of
the level of missingness.
Exposures (e.g., PM 2.5) at each follow-up will be ag-
gregated to represent chronic exposure over the study
period, as determined by the health outcomes. Analyses
will be stratified to assess consistency across communi-
ties (rural and peri-urban) and be combined to obtain an
overall risk estimate. In the combined analysis, we will
adjust for community-level confounders.
We will examine repeated measurements of SGRQ by
treatment group and carry out exploratory analyses to
consider effects of the intervention over time. The
SGRQ has previously been shown to have a standard
deviation of 19.5 points in a similar population and a
minimal clinically important difference of 4 points (a
previous study involving low-dose theophylline resulted
in a 7.8 point difference between intervention and con-
trol) [15]. A sample of 99 participants with COPD total
will be needed to produce an 80% two-sided confidence
interval that excludes a 4-point difference in SGRQ
under the scenario of a 7.8 point difference in means
[40]. We anticipate recruitment of 110 participants to
account for attrition (55 per arm).
We will additionally conduct exploratory analysis to
compare the exposure-response relationship between
HAP and FEV1 between study arms to assess whether
theophylline attenuates the association. For the
exposure-response associations, analyses will be con-
ducted within the intervention and the control groups
separately, as well as in a combined analysis. Non-linear
associations between exposure and health outcomes will
be examined using generalized additive models and
other spline-based approaches [41]. We will estimate
whether theophylline modifies the effect of HAP on lung
function and respiratory outcomes via a principal strati-
fication approach [42–44].
For evaluation of cost effectiveness, we will utilize
measurements of the EQ-5D at baseline and months 3
and 6 to convert scores into health utility estimates
using validated conversion formulae [45]. The incremen-
tal number of QALYs gained, comparing intervention
participants to controls, can then be calculated by
measuring the longitudinal values of health utility over
the intervention period in each arm. We will adapt exist-
ing costing surveys from the parent trial in Uganda to
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adopt a societal perspective and include costs to
participants, specifically monitoring productivity losses
and costs from illness, in addition to costs of the
program and the costs to society. For purposes of the
cost-effectiveness analysis, the effectiveness of the inter-
vention will be estimated as the incremental number of
QALYs gained, as estimated from change in EQ-5D.
Uncertainty in the inputs of the cost-effectiveness
analysis will be explicitly incorporated into the cost-
effectiveness analysis using probabilistic methods.
Uncertainty in incremental costs and health benefits of
each strategy will be presented using a scatter plot (the
cost-effectiveness plane), and the probability of each
implementation strategy being considered cost-effective
for a range of thresholds will be presented using a cost-
effectiveness acceptability curve, displaying the probabil-
ity of the intervention being cost effective at various
levels of willingness-to-pay.
There is no universal benchmark for cost-effectiveness.
Therefore, we will benchmark the cost-effectiveness of the
intervention against a range of established willingness-to-
pay thresholds [46]. We will compare the ICER to the
WHO standard of gross domestic product per capita per
QALY gained [47]. We will additionally compare our
ICER to published estimates of incremental cost-
effectiveness for other similar health interventions in
Uganda. We will lastly compare the total cost of the inter-
vention to the average annual household income among
participants [46].
Data management and quality assurance
Questionnaire-based data will be collected using REDCap
(REDCap, Vanderbilt University Medical Center, Nash-
ville, TN, USA) on password-protected tablet computers
(Galaxy Tab A 10.1, Samsung Electronics Co., Suwon,
South Korea) by trained research assistants. To protect
confidentiality, all participants will be assigned a unique
identification code, which will allow data to be de-
identified and stored without identifying information.
Identifiable information will only be accessible to the inde-
pendent study physician, trial pharmacist, and members of
the DSMB. Due to the low risks associated with this inter-
vention, there are no pre-specified stopping rules though
we will conduct an interim analysis at 6months. We will
conduct monthly checks of the data to assess complete-
ness and outliers (data manager, principal investigator).
Adverse events
In previous trials, there were no significant differences
between low-dose theophylline and placebo group. The
most frequent drug-related adverse effects were stomach
discomfort, headache, insomnia, and palpitations. We
will collect data on safety and tolerability of theophylline,
placebo, and salbutamol inhalers monthly, as well as
provide contact information for study clinicians. We will
maintain a data safety and monitoring board (DSMB)
with reporting of all serious adverse events within 24 h
by a study clinician. We will utilize health monitoring
infrastructure of the parent trial to adjudicate adverse
events. Health centers will be identified based on partici-
pants’ residence and patients will be referred and trans-
ported for health-related events. The DSMB will audit
trial conduct and adverse events every 12 months. Provi-
sions for ancillary and post-trial care will be provided
through trial insurance. We will report all adverse events
in follow-up publication.
Role of funder
This study is funded by the National Institutes of Health
(NHLBI/NIH). Peer review of the original grant applica-
tion contributed to the final study design. A representa-
tive of the funder may attend DSMB meetings, though
the funder otherwise has no role in the conduct or ana-
lyses of the study.
Dissemination and data sharing
The study results will be submitted for publication in
peer-review journals and presentation at international
meetings. Authorship will be determined by Inter-
national Committee of Medical Journal Editors guide-
lines. The results will be additionally provided to the
Ugandan Ministry of Health to develop national guide-
lines. We will make limited, de-identified datasets avail-
able for reproduction of any published analysis.
Discussion
This article discusses the rationale, methods and proto-
cols for the LODOT-BCOPD randomized controlled
trial in Uganda. The overall goal of the trial is to evalu-
ate clinical efficacy and cost-effectiveness of low-dose
theophylline treatment for biomass-associated COPD in
a rural community in Uganda, in the absence of long-
acting bronchodilators and/or inhaled corticosteroids.
This study will include a total of 110 patients random-
ized in a 1:1 ratio to low-dose theophylline or placebo.
Data will be collected to evaluate health-status improve-
ment with widely used and locally validated question-
naires. In addition, lung function and biomarker testing
will provide objective data to compare the two groups.
Finally, analysis will evaluate the cost-effectiveness for
the therapy, which is paramount for a disease that
disproportionately affects LMICs. This study will be
conducted in Nakaseke, Uganda, by a local and multi-
national research group with extensive experience
conducting research in the region. This local experience
will assist in navigating economic and cultural barriers
to enrollment and allow community buy-in. This clinical
trial builds upon previous research and collaborations in
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LMIC settings [17]. This previous research created well
defined cohorts of patients with biomass COPD and has
laid the groundwork for community partnerships that
will facilitate recruitment and trust in the trial interven-
tions. Furthermore, previous work has built capacity in
the region and educated Ugandan nurses, physicians,
and CHWs in research design and implementation.
This study has the potential to change the way we
understand and treat biomass-associated COPD. Cur-
rently, there are no treatments that have been formally
studied for biomass-associated COPD. Furthermore, in
LMICs, where this disease is prevalent, standard COPD
treatments are not widely available and unaffordable.
This trial, if successful, could change the treatment strat-
egy for millions of patients worldwide with this disorder
and is scalable given the ease of administration and low
cost.
Trial status
Enrollment for LODOT-BCOPD started on February
23rd 2021. Estimated date of completion is March 1
2023. Protocol version 1.4, March 1, 2021.
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